Program
pembrolizumab
Also written as “Pembrolizumab”, “Pembrolizumab 200 mg” and “NGM707 plus pembrolizumab (KEYTRUDA®)”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Melanoma · Squamous Cell Carcinoma of Head and Neck · Stomach Neoplasms · Urinary Bladder Neoplasms, led by 8 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 13824 open or running | phase 4since Oct 19, 2018 | Feb 10, 2011 | Nov 20, 2026phase 3 · NCT04634877 |
| Novartis | 30 open or running | phase 2since May 15, 2019 | Dec 12, 2013 | none ahead |
| PDS Biotechnology | 20 open or running | phase 3since Jan 14, 2025 | Feb 5, 2020 | none ahead |
| ago-research-gmbh | 11 open or running | phase 2since May 11, 2023 | May 11, 2023 | Oct 30, 2027phase 2 · NCT05903833 |
| evernov-medicines-zhuhai-hengqin-co-ltd | 10 open or running | phase 2since Dec 29, 2020 | Dec 29, 2020 | none ahead |
| mediclinic-middle-east | 10 open or running | phase 2since Mar 14, 2019 | Mar 14, 2019 | none ahead |
| NovoCure | 11 open or running | phase 3since Aug 13, 2024 | Aug 13, 2024 | Apr 2029phase 3 · NCT06556563 |
| tiumbio-co-ltd | 11 open or running | phase 2since Feb 20, 2023 | Feb 20, 2023 | Dec 2026phase 2 · NCT05784688 |
Also a collaborator on its studies: Pfizer, Eisai, Astellas Pharma, novotech-australia-pty-limited and medidata-solutions.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 50 studies since Dec 13, 2018.
- Oct 28, 2021Phase 3 study in Ovarian NeoplasmsMerck · NCT05116189 · 643 enrolled · United States, Australia, Belgium and more
- Dec 20, 2021Phase 3 study in Endometrial NeoplasmsMerck · NCT05173987 · 280 enrolled · United States, Australia, Belgium and more
- Feb 4, 2022Phase 3 study in Colorectal NeoplasmsMerck · NCT05239741 · 100 enrolled · China
- Feb 20, 2023tiumbio-co-ltd's first study: phase 2 study in Biliary Tract NeoplasmsNew to tiumbio-co-ltdtiumbio-co-ltd · NCT05784688 · 140 planned · United States, Korea, Republic of
- May 11, 2023ago-research-gmbh's first study: phase 2 study in Vulvar NeoplasmsNew to ago-research-gmbhago-research-gmbh · NCT05903833 · 42 planned · Germany
- Oct 19, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungMerck · NCT06099782 · 147 enrolled · United States, Argentina, Australia and more
- Aug 13, 2024NovoCure's first study: phase 3 study in GlioblastomaNew to NovoCureNovoCure · NCT06556563 · 741 enrolled · United States, Canada, Czechia and more
- Jan 14, 2025Phase 3 study in Head and Neck NeoplasmsPDS Biotechnology · NCT06790966 · 12 enrolled · United States
- Dec 11, 2025Phase 2 study in NeoplasmsMerck · NCT07302347 · 20 planned · Japan
- Aug 28, 2026Phase 4 study in NeoplasmsMerck · NCT07801027 · 150 planned
- Sep 28, 2026Phase 3 study terminatedStudy stoppedNCT03833167 · “The study stopped due to futility”
- Sep 28, 2026Phase 3 study terminatedStudy stoppedNCT03834493 · “The study stopped due to futility”
- Sep 28, 2026Phase 3 study terminatedStudy stoppedNCT04191096 · “The study stopped due to futility”
- Oct 2, 2026Primary completion moved from 2026-11-06 to 2027-02-12Date moved laterphase 2 · +3 months · NCT03407144
Ahead
- Nov 20, 2026Primary completion: phase 3 study in Endometrial NeoplasmsMerck · NCT04634877
- Dec 2026Primary completion: phase 2 study in Biliary Tract Neoplasmstiumbio-co-ltd · NCT05784688
- Jan 31, 2027Primary completion: phase 3 study in Urinary Bladder NeoplasmsMerck · NCT04241185
- May 5, 2027Primary completion: phase 3 study in Lung NeoplasmsMerck · NCT04380636
TargetBeta
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
The newest 60 of 148 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07801027Neoplasms | 4 | Not yet recruiting | Merck | Jan 31, 2030 | 150 |
| NCT07302347Neoplasms · Japan | 2 | Recruiting | Merck | Mar 30, 2029 | 20 |
| NCT06790966Head and Neck Neoplasms · United States | 3 | Terminated | PDS Biotechnology | Aug 25, 2026 | 12 |
| NCT06556563Glioblastoma · United States, Canada, Czechia and more | 3 | Active, not recruiting | NovoCure | Apr 2029 | 741 |
| NCT06099782Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 2 | Active, not recruiting | Merck | Apr 9, 2025 | 147 |
| NCT05903833Vulvar Neoplasms · Germany | 2 | Recruiting | ago-research-gmbh | Oct 30, 2027 | 42 |
| NCT05784688Biliary Tract Neoplasms · United States, Korea, Republic of | 2 | Recruiting | tiumbio-co-ltd | Dec 2026 | 140 |
| NCT05239741Colorectal Neoplasms · China | 3 | Active, not recruiting | Merck | Sep 19, 2028 | 100 |
| NCT05173987Endometrial Neoplasms · United States, Australia, Belgium and more | 3 | Active, not recruiting | Merck | May 27, 2027 | 280 |
| NCT05116189Ovarian Neoplasms · United States, Australia, Belgium and more | 3 | Active, not recruiting | Merck | Mar 5, 2025 | 643 |
| NCT05008224Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Australia, Canada and more | 2 | Completed | Merck | Oct 11, 2023 | 146 |
| NCT04956692Carcinoma, Non-Small-Cell Lung · United States, Brazil, France and more | 3 | Completed | Merck | Apr 4, 2023 | 531 |
| NCT04934722Parkinson Disease 4, Autosomal Dominant Lewy Body · China | 3 | Completed | Merck | Oct 31, 2022 | 186 |
| NCT04924062Parkinson Disease 4, Autosomal Dominant Lewy Body · China | 3 | Completed | Merck | Dec 15, 2022 | 158 |
| NCT04907227Prostatic Neoplasms · China | 3 | Terminated | Merck | Aug 3, 2022 | 81 |
| NCT04895358Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Merck | Apr 24, 2026 | 342 |
| NCT04882241Stomach Neoplasms · China | 3 | Completed | Merck | Feb 16, 2024 | 120 |
| NCT04875195Hodgkin Disease · United States, Brazil, Canada and more | 2 | Completed | Merck | Dec 14, 2023 | 66 |
| NCT04865289Endometrial Neoplasms · China | 3 | Completed | Merck | Oct 2, 2023 | 130 |
| NCT04859582Stomach Neoplasms · China | 3 | Withdrawn | Merck | Nov 29, 2024 | 0 |
| NCT04776148Colorectal Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Merck | Sep 27, 2024 | 563 |
| NCT04704219Carcinoma, Renal Cell · United States, Australia, Canada and more | 2 | Completed | Merck | Jan 27, 2025 | 160 |
| NCT04700124Urinary Bladder Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Merck | Oct 27, 2025 | 808 |
| NCT04699643Advanced Solid Tumors · China | 2 | UNKNOWN | evernov-medicines-zhuhai-hengqin-co-ltd | Jun 2023 | 80 |
| NCT04662710Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Argentina, Australia and more | 3 | Completed | Merck | Oct 29, 2024 | 895 |
| NCT04634877Endometrial Neoplasms · United States, Argentina, Austria and more | 3 | Active, not recruiting | Merck | Nov 20, 2026 | 990 |
| NCT04624204Small Cell Lung Carcinoma · United States, Australia, Belgium and more | 3 | Active, not recruiting | Merck | Oct 28, 2027 | 672 |
| NCT04489888Squamous Cell Carcinoma of Head and Neck · United States, Argentina, Australia and more | 4 | Completed | Merck | Feb 20, 2023 | 101 |
| NCT04428151Squamous Cell Carcinoma of Head and Neck · United States, Australia, Brazil and more | 2 | Completed | Merck | May 31, 2024 | 408 |
| NCT04380636Lung Neoplasms · United States, Argentina, Canada and more | 3 | Active, not recruiting | Merck | May 5, 2027 | 870 |
| NCT04317066Lymphoma, B-Cell · Japan | 1 | Completed | Merck | Apr 11, 2024 | 7 |
| NCT04260126Head and Neck Neoplasms · United States, Ireland, Puerto Rico and more | 2 | Completed | PDS Biotechnology | May 14, 2025 | 95 |
| NCT04246177Carcinoma, Hepatocellular · United States, Australia, Brazil and more | 3 | Terminated | Merck | Aug 19, 2025 | 480 |
| NCT04241185Urinary Bladder Neoplasms · United States, Australia, Chile and more | 3 | Active, not recruiting | Merck | Jan 31, 2027 | 520 |
| NCT04221945Uterine Cervical Neoplasms · United States, Australia, Austria and more | 3 | Completed | Merck | Jan 7, 2025 | 1,060 |
| NCT04210115Esophageal Squamous Cell Carcinoma · United States, Argentina, Belgium and more | 3 | Completed | Merck | Jan 21, 2026 | 703 |
| NCT04191096Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Australia, Austria and more | 3 | Terminated | Merck | Oct 31, 2022 | 1,251 |
| NCT04153565Mesothelioma · Japan | 1 | Completed | Merck | Sep 21, 2022 | 19 |
| NCT04123366Solid Tumors · United States, Argentina, Australia and more | 2 | Completed | Merck | Jun 8, 2026 | 333 |
| NCT04003636Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Argentina, Australia and more | 3 | Completed | Merck | Dec 15, 2022 | 1,069 |
| NCT03976375Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Completed | Merck | Aug 11, 2023 | 422 |
| NCT03968419Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more | 2 | Terminated | Novartis | Apr 20, 2022 | 88 |
| NCT03950674Carcinoma, Non-Small-Cell Lung · Japan | 3 | Completed | Merck | May 20, 2019 | 40 |
| NCT03933449Esophageal Neoplasms · China | 3 | Completed | Merck | Feb 13, 2019 | 123 |
| NCT03924895Urinary Bladder Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Merck | Jun 6, 2025 | 595 |
| NCT03924869Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Terminated | Merck | Jun 11, 2024 | 448 |
| NCT03924856Urinary Bladder Neoplasms · United States, Australia, Belgium and more | 3 | Completed | Merck | Jan 26, 2026 | 907 |
| NCT03884101Endometrial Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Merck | Oct 2, 2023 | 842 |
| NCT03881111Esophageal Neoplasms · China | 3 | Withdrawn | Merck | May 11, 2021 | 0 |
| NCT03879174Breast Cancer Female · United Arab Emirates | 2 | UNKNOWN | mediclinic-middle-east | Aug 1, 2022 | 25 |
| NCT03875092Carcinoma, Non-Small-Cell Lung · China | 3 | Completed | Merck | Sep 30, 2020 | 125 |
| NCT03867084Carcinoma, Hepatocellular · United States, Argentina, Australia and more | 3 | Completed | Merck | Mar 20, 2025 | 959 |
| NCT03850444Carcinoma, Non-Small-Cell Lung | 3 | Completed | Merck | Sep 4, 2018 | 262 |
| NCT03834519Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Merck | Mar 14, 2022 | 793 |
| NCT03834506Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Merck | Jun 20, 2022 | 1,030 |
| NCT03834493Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Terminated | Merck | Dec 12, 2022 | 1,244 |
| NCT03833167Carcinoma, Squamous Cell · United States, Argentina, Australia and more | 3 | Terminated | Merck | Jun 28, 2024 | 450 |
| NCT03797326Triple Negative Breast Neoplasms · United States, Argentina, Australia and more | 2 | Completed | Merck | Oct 28, 2024 | 611 |
| NCT03783078Carcinoma, Merkel Cell · United States, Australia, Canada and more | 3 | Completed | Merck | Feb 15, 2022 | 55 |
| NCT03776136Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Australia, Canada and more | 2 | Completed | Merck | Oct 11, 2023 | 103 |
How it is read
Names in the registry
- “Pembrolizumab”, 124 entries
- “pembrolizumab”, 29 entries
- “Pembrolizumab 200 mg”, 7 entries
- “NGM707 plus pembrolizumab (KEYTRUDA®)”, 4 entries
- “GV20-0251 and Pembrolizumab [KEYTRUDA®]”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 30 studies
- Melanoma, 14 studies
- Squamous Cell Carcinoma of Head and Neck, 10 studies
- Stomach Neoplasms, 10 studies
- Urinary Bladder Neoplasms, 9 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.